1 Name
- This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 11).
- This instrument may also be cited as PB 125 of 2024.
2 Commencement
- Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 December 2024 | 1 December 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
- Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 84AAA(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
- Schedule 1, after entry for Clonazepam in the form Tablet 2 mg
insert:
- Schedule 1, after entry for Deucravacitinib
insert:
Dienogest | Tablet 2 mg | 20 | 28 | 5 | |
- Schedule 1, after entry for Ezetimibe in the form Tablet 10 mg
insert:
- Schedule 1, entry for Medroxyprogesterone
omit:
| Injection containing medroxyprogesterone acetate 150 mg in 1 mL | 20 | 1 | 1 | |
- Schedule 1, entry for Varenicline
substitute:
Varenicline | Box containing 11 tablets 0.5 mg and 42 tablets 1 mg | 20 | 1 | 0 | |
| Tablet 1 mg | 20 | 56 | 2 | |
| | 20 | 112 | 0 | |
- Schedule 2, after entry for Ezetimibe in the form Tablet 10 mg
insert:
